Two Sigma Investments
KAPA

Two Sigma Investments’s Kairos Pharma KAPA Stock Holding History

Two Sigma Investments’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1K Sell
39,543
-54,465
-58% -$36.5K ﹤0.01% 4506
2025
Q4 		$66.7K Buy
94,008
+48,219
+105% +$45.1K ﹤0.01% 3897
2025
Q3 		$53.6K Buy
+45,789
New +$52.3K ﹤0.01% 3540

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Two Sigma Investments's KAPA Position: Q1 2026 in Review

Two Sigma Investments reduced its Kairos Pharma (KAPA) stake by 58% in Q1 2026, selling an estimated $36.5K and leaving 39,543 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4506.

Two Sigma Investments first reported a position in KAPA in Q3 2025 and has held it in 3 quarters since. The position peaked at $66.7K in Q4 2025. 11 funds tracked by Wall St. Rank hold KAPA as of Q1 2026.

  • Two Sigma Investments held 39,543 shares of Kairos Pharma worth $22.1K as of Q1 2026.
  • Two Sigma Investments sold 54,465 Kairos Pharma shares in Q1 2026, an estimated $36.5K.
  • Kairos Pharma made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4506 holding.
  • Two Sigma Investments first reported a position in Kairos Pharma in Q3 2025 and has held it in 3 quarters since.
  • Two Sigma Investments's Kairos Pharma position peaked at $66.7K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.